Abstract: A method includes receiving radar parameters from a unit under test (UUT). The method also includes generating a simulated radar return for the UUT using at least one graphics processing unit (GPU), where the simulated radar return includes digital signals. The method further includes controlling a timing of output of the simulated radar return to the UUT using at least one field programmable gate array (FPGA) carrier. The method also includes converting the digital signals into analog signals using multiple digital-to-analog converters (DACs). In addition, the method includes transmitting the analog signals to the UUT.

Abstract: A method includes receiving radar parameters from a unit under test (UUT). The method also includes generating a simulated radar return for the UUT using at least one graphics processing unit (GPU), where the simulated radar return includes digital signals. The method further includes controlling a timing of output of the simulated radar return to the UUT using at least one field programmable gate array (FPGA) carrier. The method also includes converting the digital signals into analog signals using multiple digital-to-analog converters (DACs). In addition, the method includes transmitting the analog signals to the UUT.

Abstract: Disclosed are various embodiments relating to verifying a printed work comprises a correct number of pages. Associated with a stack comprising one or more pages is an identifier that may be used to obtain an expected value for a physical characteristic of the pages in the stack. A sensor may then measure an actual value for the physical characteristic of the pages in the stack. Before binding the pages in the stack, the expected value may be compared to the actual value in order to verify the stack comprises the correct number of pages.

Abstract: Disclosed are various embodiments relating to verifying a printed work comprises a correct number of pages. Associated with a stack comprising one or more pages is an identifier that may be used to obtain an expected value for a physical characteristic of the pages in the stack. A sensor may then measure an actual value for the physical characteristic of the pages in the stack. Before binding the pages in the stack, the expected value may be compared to the actual value in order to verify the stack comprises the correct number of pages.

Abstract: Disclosed are various embodiments relating to verifying a printed work comprises a correct number of pages. Associated with a stack comprising one or more pages is an identifier that may be used to obtain an expected thickness of the pages in the stack. A sensor may then measure an actual thickness of the pages in the stack. Before binding the pages in the stack, the expected thickness of the stack may be compared to the actual thickness of the stack in order to verify the stack comprises the correct number of pages.

Abstract: Disclosed are orally deliverable pharmaceutical compositions of 2′-deoxy-2′-(fluoromethylene)cytidine (“FMdC”) and methods for providing enhanced bioavailability of FMdC in vivo.

Abstract: Methods and compositions are provided for the treatment of a host suffering from a cellular proliferative disease. In the subject methods, antiproliferative agents are administered in a substantially non-aqueous gel delivery vehicle comprising at least one polar organic solvent in combination with one or more thickening agents. The subject methods and compositions provide for the enhanced efficacy of regionally or locally administered antiproliferative proliferative agents.

Abstract: Methods and compositions are provided for the treatment of a host suffering from a cellular proliferative disease. In the subject methods, antiproliferative agents are administered in a substantially non-aqueous gel delivery vehicle comprising at least one polar organic solvent in combination with one or more thickening agents. The subject methods and compositions provide for the enhanced efficacy of regionally or locally administered antiproliferative proliferative agents.

Abstract: Methods of treating cancer by administration of FMdC followed by administration of a platinate are disclosed.

Abstract: Methods and compositions are provided for the treatment of a host suffering from a cellular proliferative diease. In the subject methods, antiproliferative agents are administered in a substantially non-aqueous gel delivery vehicle comprising at least one polar organic solvent in combination with one or more thickening agents. The subject methods and compositions provide for the enhanced efficacy of regionally or locally administered antiproliferative proliferative agents.

Abstract: Methods and compositions are provided for the treatment of a host suffering from a cellular proliferative disease. In the subject methods, antiproliferative agents are administered in a substantially non-aqueous gel delivery vehicle comprising at least one polar organic solvent in combination with one or more thickening agents. The subject methods and compositions provide for the enhanced efficacy of regionally or locally administered antiproliferative proliferative agents.

Abstract: The present invention relates to tezacitabine ((E)-2′-fluoromethylene-2′-deoxycytidine) formulations which are stable for long periods of time. The present invention further relates to methods of formulating stable tezacitabine formulations.

Abstract: Methods of treating cancer by administration of FMdC followed by administration of a platinate are disclosed.

Abstract: Methods of treating cancer by administration of FMdC followed by administration of a platinate are disclosed.

Abstract: Disclosed are orally deliverable pharmaceutical compositions of 2′-deoxy-2′-(fluoromethylene)cytidine (“FMdC”) and methods for providing enhanced bioavailability of FMdC in vivo.

Abstract: An improved diluent for the preparation of cisplatin suspensions from a lyophilized powder is provided. The diluent contains a pharmaceutically acceptable nonionic surfactant, which improves the accuracy and homogeneity of the therapeutic formulation. The suspension may be used directly, or may be used in preparing gel formulations for direct injection into a neoplastic lesion or surrounding tissue.

Abstract: A medical fastening system for a modular knee prosthesis system includes a femoral component having a first surface, a second surface, and an aperture extending therebetween. A modular adapter element has a first end that is mountable adjacent the first surface of the femoral component and a second, mating end that is engagable with a second prosthesis component. The system also includes a first bolt that mates the adapter element to the femoral component. Various connection options are possible to secure different components of the system to each other.

Abstract: An improved diluent for the preparation of cisplatin suspensions from a lyophilized powder is provided. The diluent contains a pharmaceutically acceptable nonionic surfactant, which improves the accuracy and homogeneity of the therapeutic formulation. The suspension may be used directly, or may be used in preparing gel formulations for direct injection into a neoplastic lesion or surrounding tissue.

Abstract: Disclosed are proteinaceous compositions comprising collagen and an effective amount of a compatible cytotoxic drug which compositions are characterized by having a single collagen transition temperature of less than about 45.degree. C. Such compositions possess enhanced retention of the cytotoxic drug at the site of injection and are optically translucent.

Abstract: Conductive and/or chemically absorptive ceramic fibers are woven with optional non-conductive/non-absorptive ceramic fibers to create a fiber reinforcement which is impregnated with a ceramic-material-producing (pre-ceramic polymer) binder and heated to create the ceramic honeycomb with controlled ohmic loss and/or chemical absorption properties. The desired properties of the honeycomb material can be provided by the conductive and/absorptive ceramic fibers alone or in combination with non-fibrous or fibrous conductive and/or absorptive ceramic material provided by the binder, typically a preceramic polymer which may or may not contain dispersed ceramic materials; after the honeycomb is formed, the non-fibrous or fibrous conductive and/or absorptive ceramic material is interspersed throughout the honeycomb. By heating the impregnated fiber reinforcement in the absence of oxygen, carbon from any carbon-containing materials within the binder remain as a part of the honeycomb material.